Turning Innovation into Clinical Advantage for Faster Patient Access
The process of biopharmaceutical clinical evidence development is undergoing dramatic change. Technological innovation, novel development strategies, and regulators’ growing acceptance of alternatives to traditional trials are converging to improve how clinical evidence is generated. Some changes have already happened, others are in process, and further evolution is inevitable.
For sponsors, this shift has meaningful business implications. New approaches to drug clinical trials can enable organizations to reach key development milestones faster, with fewer delays and more predictable outcomes. That benefits patients, sponsors, and regulators alike. It can also help sponsors preserve commercial value by accelerating time to market and extending the period in which products can be sold under patent protection.
As this new era of evidence development takes shape, life science companies and technology providers should assess whether their clinical evidence strategies, data infrastructure, validation practices, and operating models are ready to support it.
Regulatory Modernization Is Creating New Pathways
Regulators around the world have signaled their willingness to accept new approaches to the conduct of clinical trials to accelerate and improve the process. Among other existing and proposed initiatives, the June 2026 Operation Trailblazer: HHS Roadmap to Maintaining U.S. Leadership in Early Clinical Research and Development outlines a multi-agency intent to revitalize U.S. leadership in global pharmaceutical development.
As part of Operation Trailblazer, FDA issued FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development, which elaborates strategies for “eliminating unnecessary regulatory burden, clarifying phase-appropriate requirements, and building partnerships with government, academic medical centers and the private sector.” Protecting and promoting public health should not be viewed primarily as rivalry with other countries. Still, it is unquestionably important to bring valuable treatments to patients more quickly and reduce the burden of product development on sponsors without compromising safety and effectiveness expectations.
Why the Traditional Clinical Trial Model Is Under Pressure
The most costly and time-consuming step in gaining regulatory approval and market access is developing the requisite clinical evidence. Traditional large, randomized, double-blinded clinical trials have long been the gold standard of new drug development, but they are cumbersome, costly, constrained in scope, and fraught with multiple well-known problems.
Challenges with conventional clinical trials include patient recruitment and retention, efficient and consistent site and data management, site and subject training and communication, overly restrictive inclusion and exclusion criteria, ethical constraints on animal and human studies, risks to human subjects, and the difficulty of designing studies for rare diseases or patients with comorbidities.
New Approaches to Clinical Evidence Development
Innovative, more nimble alternatives to animal and human studies have the potential to achieve the same level of confidence in less time and at lower cost, with less risk and inconvenience to study subjects. In some cases, these approaches can generate credible evidence that was not feasible using conventional methods.
These include but are not limited to:
Computational Modeling and Simulation
Computational modeling and simulation makes it possible to generate vast study populations, including vulnerable patients normally excluded from clinical trials, and to examine sub-populations and patients with rare diseases or comorbidities that would be challenging or impossible to study with conventional trial methods. Validated in silico trials can help guide the correct trial design and study population, consequently streamlining a smaller and better-focused human study that puts fewer subjects at lowered risk.
With some medical devices and diagnostics, in silico trials can replace human clinical trials altogether. This does not yet seem feasible in drug development due to the complexity of the human metabolic system, though this may change in the future.
Non-Animal Models
In addition to computational modeling, technologies such as organ-on-a-chip and human cell-based assays can replace early-stage animal studies, yielding more reliable results by using actual human tissues. For example, disembodied human brains from deceased donors have been used to more realistically identify the metabolism of drugs for neurodegenerative diseases.
Decentralized Trials and Virtual Visits
The problems of recruiting and retaining a mix of subjects truly representative of the ultimate target patient population can be reduced using decentralized trials, virtual visits, and wearable data collection. More people are willing or able to participate in trials that are less burdensome. More immediate data communication can also alert study staff when there are problems and facilitate more nimble use of adaptive clinical trials.
Artificial Intelligence
Artificial intelligence is having an impact on drug clinical evidence development as it is in many other fields. Applications continue to expand rapidly, but through its ability to aggregate information from many sources, AI is already being employed in study protocol design, patient recruitment and retention, site selection based on known site performance, trial monitoring, data management, and to support Bayesian adaptive trial designs.
Real World Evidence
The use of real-world evidence provides clinical data from actual, representative medical practice and experimental research. When used appropriately, real-world data can supplement and enhance controlled studies. FDA also recognizes the value in reusing data from one product to support the next rather than expecting sponsors to start fresh with each new product submission, and in taking advantage of toxicology and other data from well-understood product classes instead of requiring the time and expense of fresh animal studies.
Adaptive Trial Designs
Adaptive trial designs can help sponsors make better-informed decisions as evidence emerges during a study. When supported by timely data flows and appropriate statistical planning, adaptive approaches can improve development efficiency while maintaining scientific rigor.
Technologies for Coordinating Sites and Managing Data
New technologies for coordinating sites and managing data can improve consistency, visibility, and responsiveness across clinical trial operations. These capabilities are especially important as trials become more distributed, data-intensive, and dependent on real-time communication among sponsors, investigators, and participants.
Communication and Training for Investigators and Study Subjects
Improving communication and training for both investigators and study subjects can reduce variability, support protocol adherence, and improve the participant experience. As clinical trials incorporate more decentralized tools, digital data collection, and novel study methods, clear expectations and training become essential to reliable execution
Master Protocols Can Reduce Duplication and Increase Learning
Beyond these approaches, regulators are also encouraging broader trial structures that can generate more evidence with less duplication.
In recent years, regulators have accepted and encouraged alternatives to conventional clinical studies in new product evaluation, as well as organizational changes aimed at streamlining the process. FDA has eased away from the requirement for two well-controlled trials and accepts results from a single trial with confirmatory evidence. A proposal for accelerating the IND process includes the use of external advisors and reviewers and the use of rolling INDs. The Agency also recognizes the need to clarify the hitherto ambiguous requirements for beginning first-in-human trials so that sponsors can more efficiently generate and provide the information required.
A June 2026 FDA draft guidance on Master Protocols for Drug and Biological Product Development outlines approaches that would maximize the information generated by studies while shared protocols and data can reduce the burden of needlessly duplicative efforts. These include umbrella trials that evaluate multiple drugs concurrently for a single disease or condition, basket trials that evaluate a single drug for multiple diseases, conditions, or disease subtypes, and platform trials that evaluate multiple drugs for one or more diseases or conditions in an ongoing manner.
Modernization Does Not Mean Simplification
These new approaches can accelerate the evidence development process and efficiently generate more useful information than is possible with conventional trials, but they do not always reduce or simplify the work involved. Proper validation of novel study methods and technologies assumes critical importance. The design of studies using master protocols is significantly more complex than that of stand-alone trials. Validating computational modeling and simulation requires new knowledge and skills on the parts of both sponsors and regulators. The use of virtual visits and wearable data collection and transmission raises new cybersecurity and privacy issues, as well as different training and relationship requirements between investigators and study subjects.
Axendia’s Take
New approaches to drug clinical trials benefit patients, sponsors, and regulators. They enable drugs to reach key development milestones faster, with fewer delays and more predictable outcomes. The opportunity is not simply to accelerate development, but to generate more useful, more representative, and more actionable evidence while maintaining confidence in safety and effectiveness.
At the same time, these approaches must be implemented responsibly. Sponsors will need stronger validation practices, cross-functional expertise, data governance, cybersecurity protections, and clear regulatory alignment.
Technology providers must also deliver solutions that align with these new approaches, enabling secure, interoperable, validated, and fit-for-purpose capabilities across decentralized trials, real-world evidence, AI-enabled workflows, adaptive designs, and advanced data management.
The sponsors turning these emerging capabilities into integrated evidence strategies will be better positioned to reduce burden, improve development predictability, and bring valuable treatments to patients more quickly.
Sponsors and technology companies should use this moment to assess whether their clinical evidence strategies, data infrastructure, validation practices, solutions, and operating models are ready to support this new era of evidence development.
Ready to unlock new opportunities and drive success? Schedule an Analyst Inquiry
Stay Connected with Axendia!
Stay at the forefront of innovation and technology in life sciences, healthcare, and space-enabled research by connecting with Axendia.
- Follow us on LinkedIn: Join our professional network and stay updated on the latest insights, trends, and case studies. Connect with Axendia on LinkedIn
- Subscribe to Our Updates: Get exclusive insights and thought leadership articles delivered straight to your inbox. Sign up for our newsletter
- Share Your Thoughts: We’d love to hear from you! Contact us to discuss your ideas, challenges, or opportunities. Email Axendia
Let’s drive innovation together!
The opinions and analysis expressed in this post reflect the judgment of Axendia at the time of publication and are subject to change without notice. Information contained in this post is current as of publication date. Information cited is not warranted by Axendia but has been obtained through a valid research methodology. This post is not intended to endorse any company or product and should not be attributed as such.